Objectives: This study aims to explore the construct validity, dimensionality, and internal consistency of a new attitude scale for measuring cardiology trainees' attitudes towards clinical supervision.
Methods: A multi-centred, cross-sectional study involving 388 Indonesian cardiology trainees from eight universities was conducted using convenience sampling. Twenty-nine items have been generated based on an extensive literature review and conceptual framework of effective clinical supervision. Ten clinical experts reviewed the items to ensure the Cardiology Clinical Supervision Scale (CCSS) adequately represents the construct under study. An exploratory factor analysis using principal axis factoring (PAF) with oblique rotation was run to identify the internal structure of the scale. Items with factor loading <0.50 were deleted. In addition, inter-item correlations and items' communalities were analysed. Each subscale's internal consistency was assessed using Cronbach's alpha score.
Results: The content validity index provided evidence for CCSS' validity (G-coefficient=0.71). Scrutinising the experts' comments, we finalised the scale to include 27 items. Further, four items were deleted due to low inter-item correlation and communality. PAF analysis resulted in a two-factor model comprising the "Supervisory Interaction and Facilitation" factor (n=10 items) and the "Role Modelling" factor (n=9 items); four items were deleted due to low factor loading. The Cronbach's alpha score for SIF and RM factors were 0.93 and 0.89, respectively.
Conclusions: The study's results support the validity, internal structure, and internal consistency of the new clinical supervision scale for cardiology training. Further studies are required to investigate other validity and reliability evidence for CCSS, including its cross-cultural validity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5116/ijme.604a.4964 | DOI Listing |
Paediatr Drugs
January 2025
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
Background: This study aimed to provide a comprehensive review of adverse events (AEs) associated with factor Xa (FXa) inhibitors in pediatric patients.
Methods: We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and the European Union Clinical Trials Register for English-language records from the establishment of the database up to October 17, 2023.
Drugs
January 2025
Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust, University College London, London, NW3 2QG, UK.
Lysosomal storage disorders (LSDs) are rare inherited metabolic disorders characterized by defects in the function of specific enzymes responsible for breaking down substrates within cellular organelles (lysosomes) essential for the processing of macromolecules. Undigested substrate accumulates within lysosomes, leading to cellular dysfunction, tissue damage, and clinical manifestations. Clinical features vary depending on the degree and type of enzyme deficiency, the type and extent of substrate accumulated, and the tissues affected.
View Article and Find Full Text PDFAlzheimers Res Ther
January 2025
Department of Neurosciences, University of California, San Diego, La Jolla, CA, 92093-0948, USA.
Background: Effective detection of cognitive impairment in the primary care setting is limited by lack of time and specialized expertise to conduct detailed objective cognitive testing and few well-validated cognitive screening instruments that can be administered and evaluated quickly without expert supervision. We therefore developed a model cognitive screening program to provide relatively brief, objective assessment of a geriatric patient's memory and other cognitive abilities in cases where the primary care physician suspects but is unsure of the presence of a deficit.
Methods: Referred patients were tested during a 40-min session by a psychometrist or trained nurse in the clinic on a brief battery of neuropsychological tests that assessed multiple cognitive domains.
CNS Drugs
January 2025
Innovative Medicines and Global Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Background: Huntington disease (HD) is a progressive neurodegenerative disease that causes psychiatric and neurological symptoms, including involuntary and irregular muscle movements (chorea). Chorea can disrupt activities of daily living, pose safety issues, and may lead to social withdrawal. The vesicular monoamine transporter 2 inhibitors tetrabenazine, deutetrabenazine, and valbenazine are approved treatments that can reduce chorea.
View Article and Find Full Text PDFComput Biol Med
January 2025
IMT Atlantique, Lab-STICC, UMR CNRS 6285, team RAMBO, F-29238 Brest, France.
Rehabilitation is the process of helping people regain or improve lost or impaired function due to injury, illness, or disease. To assist in tracking the progress of patients undergoing rehabilitation, this paper proposes a lightweight graph-based deep-learning model for the automatic assessment of physical rehabilitation exercises. The model takes as input the 3D skeleton sequence of a patient performing a movement and outputs a continuous quality score, as a means for patient supervision that could complement or even substitute the need for ordinary clinical exams.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!